Valiant Laboratories Limited
NSE: VALIANTLAB BSE: VALIANTLAB
NSE
87.99
0.14 (0.16%)
Prev Close
87.85
Open Price
88.9
Volume
17,343
Today Low / High
87.51 / 88.9
52 WK Low / High
75.2 / 133.49
Range
84 - 92
BSE
88.03
0.10 (0.11%)
Prev Close
87.93
Open Price
88
Volume
1,866
Today Low / High
86.53 / 88.59
52 WK Low / High
75.86 / 136.8
Range
84 - 92
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 87.99 (target range: 84 - 92), reflecting a change of 0.14 (0.15936%). On the BSE, it is listed at 88.03 (target range: 84 - 92), showing a change of 0.1 (0.11373%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
22 Aug
88.90
-1.02%
21 Aug
88.78
-1.05%
20 Aug
88.20
-0.17%
19 Aug
89.96
-1.38%
18 Aug
89.59
0.41%
14 Aug
88.65
0.56%
13 Aug
89.51
-1.65%
12 Aug
90.80
0.23%
11 Aug
90.99
0.98%
08 Aug
93.95
-6.19%
07 Aug
93.64
-1.92%
06 Aug
92.76
0.95%
05 Aug
86.50
3.32%
04 Aug
92.99
-4.91%
01 Aug
94.00
-4.05%
31 Jul
90.50
1.25%
30 Jul
89.00
3.39%
29 Jul
90.00
-2.11%
28 Jul
93.00
-3.43%
Valiant Laboratories Limited Graph
Valiant Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Valiant Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 87.99, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 88.03 | 88.91 | 80.02 - 97.80 |
| 89.79 | 71.83 - 107.75 | ||
| 90.67 | 63.47 - 117.87 | ||
| Bearish Scenario | 88.03 | 87.15 | 78.43 - 95.86 |
| 86.27 | 69.02 - 103.52 | ||
| 85.39 | 59.77 - 111.01 |
Overview of Valiant Laboratories Limited
ISIN
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
77,587
Market Cap
3,823,250,674
Last Dividend
0
Official Website
IPO Date
2023-10-06
DCF Diff
225.22
DCF
-112
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 138.82 Cr | 116.60 Cr | 22.22 Cr | 0.1600 | 0.00 Cr | 0.00 Cr | 17.83 Cr | -2.20 Cr | -0.51 | 0.76 Cr | -0.0159 |
| 2024-03-31 | 182.06 Cr | 168.25 Cr | 13.80 Cr | 0.0758 | 0.00 Cr | 0.00 Cr | -10.37 Cr | 0.32 Cr | 0.08 | -8.60 Cr | 0.0018 |
| 2023-03-31 | 333.91 Cr | 277.32 Cr | 56.59 Cr | 0.1695 | 0.00 Cr | 0.65 Cr | 38.39 Cr | 29.00 Cr | 6.67 | 39.95 Cr | 0.0868 |
| 2022-03-31 | 291.52 Cr | 239.20 Cr | 52.32 Cr | 0.1795 | 0.00 Cr | 0.48 Cr | 40.01 Cr | 27.50 Cr | 6.33 | 44.27 Cr | 0.0943 |
| 2021-03-31 | 182.37 Cr | 123.98 Cr | 58.39 Cr | 0.3202 | 0.00 Cr | 0.56 Cr | 47.40 Cr | 30.59 Cr | 7.04 | 51.41 Cr | 0.1678 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 75.99 Cr | 400.86 Cr | 166.55 Cr | 234.3101 Cr | 121.69 Cr | 45.70 Cr | 3.99 Cr | 204.11 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 59.6157 Cr |
| 2024-03-31 | 11.72 Cr | 342.69 Cr | 105.83 Cr | 236.8612 Cr | 76.71 Cr | 64.99 Cr | 10.02 Cr | 92.70 Cr | 0.00 Cr | 0.00 Cr | -128.67 Cr | 29.0769 Cr |
| 2023-03-31 | 1.26 Cr | 212.97 Cr | 112.48 Cr | 100.4910 Cr | 60.22 Cr | 58.96 Cr | 13.04 Cr | 48.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 50.7260 Cr |
| 2022-03-31 | 0.13 Cr | 181.81 Cr | 110.35 Cr | 71.4600 Cr | 61.13 Cr | 61.00 Cr | 15.80 Cr | 23.67 Cr | 0.00 Cr | 0.00 Cr | 0.40 Cr | 49.4270 Cr |
| 2021-03-31 | 3.94 Cr | 106.31 Cr | 17.73 Cr | 88.5820 Cr | 0.60 Cr | -3.33 Cr | 6.07 Cr | 19.79 Cr | 0.00 Cr | 0.96 Cr | 0.00 Cr | 15.8870 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.3133 Cr | -52.7677 Cr | 44.6528 Cr | -112.5403 Cr | -6.8017 Cr | 4.9165 Cr | -113.8536 Cr | -2.2012 Cr | 29.6858 Cr | 0.0000 Cr | 6.0267 Cr |
| 2024-03-31 | 1.8854 Cr | -143.8768 Cr | 152.4479 Cr | -43.9849 Cr | 10.4566 Cr | 11.7182 Cr | -45.8703 Cr | -0.7695 Cr | 16.6503 Cr | 0.0000 Cr | 3.0270 Cr |
| 2023-03-31 | 56.0511 Cr | -55.1682 Cr | -0.9339 Cr | 18.3702 Cr | -0.0510 Cr | 1.2616 Cr | -37.6809 Cr | 28.9983 Cr | -1.2807 Cr | 0.0000 Cr | 2.7615 Cr |
| 2022-03-31 | 2.2510 Cr | -12.2380 Cr | 6.1810 Cr | -4.6250 Cr | -3.8060 Cr | 0.1310 Cr | -6.8760 Cr | 41.7040 Cr | -42.0720 Cr | 0.0000 Cr | -9.7310 Cr |
| 2021-03-31 | 9.1090 Cr | -16.6690 Cr | 11.4300 Cr | 7.4400 Cr | 3.8690 Cr | 3.9370 Cr | -1.6690 Cr | 47.0230 Cr | 13.2140 Cr | 0.0000 Cr | -2.2040 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 55.47 Cr | 48.23 Cr | 7.25 Cr | 0.1306 | 6.12 Cr | 0.70 Cr | 0.16 | 3.09 Cr | 0.0127 |
| 2024-12-31 | 35.23 Cr | 28.72 Cr | 6.51 Cr | 0.1848 | 0.10 Cr | 2.35 Cr | 0.54 | 2.20 Cr | 0.0666 |
| 2024-09-30 | 21.48 Cr | 20.59 Cr | 0.89 Cr | 0.0413 | -7.26 Cr | -4.74 Cr | -1.09 | -3.38 Cr | -0.2207 |
| 2024-06-30 | 18.88 Cr | 19.00 Cr | -0.12 Cr | -0.0062 | -2.92 Cr | -0.51 Cr | -0.12 | -2.48 Cr | -0.0270 |
| 2024-03-31 | 30.59 Cr | 30.00 Cr | 0.58 Cr | 0.0191 | -5.05 Cr | -1.24 Cr | -0.33 | -2.03 Cr | -0.0405 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 75.99 Cr | 0.00 Cr | 75.99 Cr | 72.12 Cr | 3.99 Cr | 192.62 Cr | 204.11 Cr | 400.86 Cr | 166.55 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 118.98 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -231.61 Cr |
| 2024-09-30 | 2.40 Cr | 116.58 Cr | 118.98 Cr | 0.03 Cr | 5.16 Cr | 191.36 Cr | 162.49 Cr | 360.96 Cr | 129.35 Cr |
| 2024-06-30 | -143.82 Cr | 287.65 Cr | 143.82 Cr | 0.00 Cr | 0.00 Cr | 143.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 11.72 Cr | 132.11 Cr | 143.82 Cr | 45.73 Cr | 10.02 Cr | 225.54 Cr | 92.70 Cr | 342.69 Cr | 105.83 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.70 Cr | 1.31 Cr | -52.77 Cr | 44.65 Cr | 4.92 Cr | 4.92 Cr | 0.00 Cr | -113.85 Cr | -112.54 Cr |
| 2024-12-31 | 2.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -4.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -0.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -1.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,641.80 | ₹3,939,137,904,000.00 | ₹2,098,280.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,151.50 | ₹1,633,032,553,500.00 | ₹681,521.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,685.30 | ₹1,247,271,358,500.00 | ₹279,863.00 |
| Mankind Pharma Limited | MANKIND | ₹2,606.80 | ₹1,075,901,331,568.00 | ₹731,305.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,277.60 | ₹1,063,387,459,020.00 | ₹1,229,762.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.80 | ₹994,960,224,000.00 | ₹307,413.00 |
| Lupin Limited | LUPIN | ₹1,974.70 | ₹901,938,300,900.00 | ₹380,522.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,426.00 | ₹648,759,690,000.00 | ₹99,581.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.40 | ₹610,074,420,800.00 | ₹1,872,840.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,937.30 | ₹546,707,997,300.00 | ₹466,930.00 |
| Laurus Labs Limited | LAURUSLABS | ₹879.10 | ₹474,560,157,500.00 | ₹1,548,001.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,418.40 | ₹359,853,753,600.00 | ₹437,395.00 |
| Cohance Lifesciences Limited | COHANCE | ₹884.70 | ₹338,457,031,978.00 | ₹105,334.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,638.50 | ₹329,643,636,000.00 | ₹49,045.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,747.90 | ₹273,268,433,900.00 | ₹250,994.00 |
| Piramal Enterprises Limited | PEL | ₹1,167.70 | ₹264,691,900,600.00 | ₹183,898.00 |
| Eris Lifesciences Limited | ERIS | ₹1,768.70 | ₹240,909,320,900.00 | ₹37,828.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,479.40 | ₹240,371,432,600.00 | ₹246,819.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,433.00 | ₹210,825,000,000.00 | ₹11,150.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹974.60 | ₹191,570,299,800.00 | ₹29,498.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,888.00 | ₹178,181,651,200.00 | ₹28,474.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,083.00 | ₹172,501,323,000.00 | ₹140,398.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,168.10 | ₹164,800,966,770.00 | ₹172,510.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹882.45 | ₹158,055,619,500.00 | ₹259,072.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹458.50 | ₹111,252,274,000.00 | ₹945,550.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,581.50 | ₹109,248,951,100.00 | ₹46,177.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹851.90 | ₹83,308,067,710.00 | ₹36,218.00 |
| Strides Pharma Science Limited | STAR | ₹865.50 | ₹79,775,471,850.00 | ₹92,326.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹863.25 | ₹78,240,335,715.00 | ₹294,141.00 |
| FDC Limited | FDC | ₹474.65 | ₹77,277,766,500.00 | ₹198,253.00 |
| Innova Captab Limited | INNOVACAP | ₹911.35 | ₹52,151,939,956.00 | ₹70,484.00 |
| Suven Life Sciences Limited | SUVEN | ₹230.75 | ₹50,320,575,500.00 | ₹56,095.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹146.08 | ₹47,406,173,760.00 | ₹195,028.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹483.05 | ₹44,087,973,500.00 | ₹160,106.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.85 | ₹44,021,409,750.00 | ₹240,104.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹772.20 | ₹39,165,289,020.00 | ₹31,316.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,358.20 | ₹39,002,269,800.00 | ₹5,512.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹363.25 | ₹36,425,983,500.00 | ₹39,528.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹502.80 | ₹35,400,036,240.00 | ₹9,585.00 |
| Hikal Limited | HIKAL | ₹254.90 | ₹31,429,424,900.00 | ₹3,140,867.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹631.60 | ₹30,413,434,800.00 | ₹53,855.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹96.82 | ₹28,419,284,140.00 | ₹848,541.00 |
| Alembic Limited | ALEMBICLTD | ₹105.52 | ₹27,095,636,534.00 | ₹249,022.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.03 | ₹26,866,184,620.00 | ₹2,369,065.00 |
| Indoco Remedies Limited | INDOCO | ₹279.55 | ₹25,787,900,445.00 | ₹12,570.00 |
Key Executives
Chief Financial Officer & Executive Director
Mr. Paresh Shashikant Shah
Gender: male
Year Born: 1960
Head Accounts & Finance
Mr. Chandrakant Mahadeo Mandhare
Gender: male
Year Born: 1978
Head of R&D
Meghana Shivpal Wasnik
Gender: Not Specified
Year Born:
Research & Development Head
Mr. Nilesh Vinayak Patil
Gender: male
Year Born: 1983
Unit Head
Mr. Jyotibhushan Singh
Gender: male
Year Born: 1972
Company Secretary & Compliance Officer
Ms. Prajakta Kantishwar Patil
Gender: female
Year Born: 1992
Executive Officer
Ms. Rachi Santosh Vora
Gender: female
Year Born:
Managing Director & Executive Director
Mr. Santosh Shantilal Vora
Gender: male
Year Born: 1994
FAQs about Valiant Laboratories Limited
Who is the CEO of the company?
The CEO is Santosh Shantilal Vora.
What is the current market price of the stock?
The current price is ₹87.99.
What is the 52-week price range?
The range is ₹75.2-133.49.
What is the market capitalization of the company?
The market capitalization is ₹382.33 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -175.77.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Valiant Laboratories Limited (ISIN: ) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹382.33 crores and an average daily volume of 77,587 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.